Filibuvir: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection

L. Kapelusznik, E. L. Heil, Z. Temesgen, R. Talwani

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the "thumb 2" pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.

Original languageEnglish (US)
Pages (from-to)767-775
Number of pages9
JournalDrugs of the Future
Issue number11
StatePublished - Nov 2012


  • Filibuvir
  • Hepatitis C virus
  • PF-868554
  • RNA-directed RNA polymerase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Filibuvir: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection'. Together they form a unique fingerprint.

Cite this